Gujarat Themis Biosyn Limited (GUJTHEM) — Announcement

· NSE Neutral

Gujarat Themis Biosyn Limited announced its Investor Presentation on June 29, 2026, detailing strategic acquisitions and capacity expansion. The filing outlines plans to acquire Sanofi's anti-TB and anti-infective portfolio and MicroBiopharm Japan, aiming to expand into biologics and novel modalities while enhancing fermentation capabilities. Key financials show FY26 revenue of INR 16,582.28 lakhs and EBITDA margin of 45.55%. The presentation emphasizes forward integration from intermediates to finished dosage forms and geographic expansion into Europe and MEA markets. The company highlights strengthened R&D infrastructure and ESG initiatives as growth drivers. This move positions GTBL as a diversified pharma platform with enhanced manufacturing depth and global market access.

📄 View Original Announcement (PDF)

About Gujarat Themis Biosyn Limited (GUJTHEM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,034.98 Cr P/E: 84.4

View full GUJTHEM stock details →

📡 Get AI alerts when GUJTHEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GUJTHEM — Free

📊 More GUJTHEM filings

See all GUJTHEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when GUJTHEM files new disclosures

Track GUJTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GUJTHEM — Free

Free account · 2 AI queries/day